Lifeward’s ReWalk Exoskeleton Shows Significant Real-World Benefits in Peer-Reviewed Study — Lifeward Ltd.

Event summary

Peer-reviewed study published in the Internet Journal of Allied Health Sciences and Practice shows ReWalk exoskeleton significantly improves daily activity performance, satisfaction, and reduces pain for users with chronic spinal cord injury.
12 participants successfully performed kitchen tasks and 10 performed grooming tasks while using the exoskeleton at home.
Study reported significant improvements in perceived ability to perform daily activities (COPM performance scores, P=.008), satisfaction with performance (COPM satisfaction scores, P=.003), and lower reported pain compared to wheelchair use (NPRS, P=.01).
Lifeward reports 13% year-over-year sales increase for ReWalk exoskeleton, contributing to a 16% increase in total revenue to $6.6 million in Q2 2026.

The big picture

The study provides robust clinical evidence supporting the real-world benefits of ReWalk exoskeleton, which could accelerate adoption among patients, clinicians, and payers. Lifeward's strategic focus on expanding distribution and broadening access aligns with broader industry trends toward home-based rehabilitation solutions. The company's 16% revenue increase in Q2 2026 underscores the growing market demand for advanced neurorehabilitation technologies.

What we're watching

Clinical Validation: How the peer-reviewed study will influence clinician and payer adoption of ReWalk exoskeleton.
Market Expansion: The pace at which Lifeward can scale distribution through partnerships like Ottobock Care.
Revenue Growth: Whether Lifeward can sustain the 13% year-over-year sales increase for ReWalk amid broader market conditions.